Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a leukodystrophy characterized by early-onset macrocephaly and delayed-onset neurological deterioration.
Introduction
Megalencephalic leukoencephalopathy with subcortical cysts (MLC, MIM 604004) is a leukodystrophy with autosomal-recessive inheritance 1 . Patients develop macrocephaly during the first year of life. After several years, there is evidence of slow neurological deterioration, including cerebellar ataxia, spasticity, epilepsy, and mild cognitive decline. From early on, magnetic resonance imaging (MRI) reveals diffuse signal abnormality and swelling of the brain white matter and subcortical cysts ( Supplementary Fig. 1 , available online) 1 . In follow-up exams, the white matter abnormalities remain and atrophy ensues 1 . A brain biopsy from an MLC patient showed extensive myelin vacuolation, mainly affecting the outer myelin layers, which causes the swollen appearance of the white matter 2 . In 2001, we demonstrated that mutations in MLC1 (MIM 605908) cause MLC 3 . MLC1 mutations are found in approximately 75% of the MLC patients 4 . MLC1 is an oligomeric membrane protein that is expressed almost exclusively in the brain. It has some degree of homology to ion channels 5, 6 . Within the brain, MLC1 is mainly located in astrocyte-astrocyte junctions close to blood-and cerebrospinal fluid (CSF)-brain barriers, Bergmann glia, and main axonal tracts [5] [6] [7] . Thus far, the physiological role of MLC1 has remained unknown, and a suggested role in ion transport has not been confirmed 3, 5, 8 .
In some families, members with MLC do not have MLC1 mutations, and these families do not show linkage to the MLC1 locus, indicating that mutations in at least one other gene are involved in MLC 9,10 , but genetic-linkage studies failed to identify another disease gene.
We recently described two distinct phenotypes among MLC patients without MLC1 mutations 11 . The classical phenotype retains typical clinical and MRI features, as seen in patients with MLC1 mutations 1, 11 . The second, improving phenotype is initially the same as the classical phenotype but lacks clinical deterioration and shows major improvement or normalization of the MRI abnormalities 11 ( Supplementary Fig. 1 ).
Because of the unsuccessful genetic-linkage studies and the possibility of further genetic heterogeneity, we decided to use alternative strategies to identify eligible candidate genes.
Material and Methods
The studies on human samples were performed with approval of the institutional review board, 
Preparation of Source Material
Plasma membrane-enriched protein fractions were prepared from pools of freshly isolated whole rat or mouse brains according to the procedure used in Zolles et al. 12 . For solubilization, the prepared membrane vesicles were resuspended in ComplexioLyte buffer 47a (at 0.8 mg protein/ml, LOGOPHARM GmbH, Germany; with protease inhibitors added) and incubated for 30 min at 4°C; nonsoluble components were removed afterward by ultracentrifugation (10 min at 150.000 × g). Efficiency of solubilization was determined by immunoblot analysis of SDS-PAGE-resolved aliquots of solubilisate and pellet fractions.
Polyvinylidene fluoride (PVDF) membranes were probed with rabbit polyclonal antibodies (α-N1 or α-NH, 1:10.000, see below), stained with goat anti-rabbit-HRP (Santa Cruz Biotechnologies, USA) and developed with ECL+ (GE Healthcare, USA)
Affinity Purification
For each experiment, 1.5 ml freshly prepared solubilisate (rat or mouse) was incubated for 2 hr at 4°C with 20 µg of the respective immobilized antibody 13 (α-N1, α-N2 α-NH, α-
. After a brief washing (twice for 5 min each time) with ComplexioLyte 47a, bound proteins were eluted with Laemmli buffer (dithiothreitol [DTT] was added after elution). Eluates were then briefly run on SDS-PAGE gels followed by silver staining and tryptic digestion. During these experiments, samples were taken for immunoblot analysis with the indicated MLC1 and GlialCAM antibodies.
Preparation of Myelin
Myelin was prepared as described previously 14 . Two brains from 6-to 8-week-old wild-type mice were homogenized in 20 volumes of homogenization buffer (0.32 M sucrose in 10 mM HEPES [pH 7.4]) with five strokes with a loose pestle and seven strokes with a tight pestle.
The homogenate was layered over 0.85 M sucrose, centrifuged at 25,000 rpm for 30 min in a swinging bucket rotor. Proteins located in the interphase were removed, resuspended in 10 volumes of water, and centrifuged at 25,000 rpm for 15 min. The pellet was twice cleansed of sucrose by water suspension and centrifugation. Then, pellets were suspended again in homogenization buffer and layered over 0.85 M sucrose and centrifuged at 25,000 rpm for 30 min. The interphase layer was again suspended in water, centrifuged for 15 min, and resuspended in 10 mM HEPES buffer (pH 7.4) containing 1% Triton X-100. Protein was quantified by bicinchoninic acid, and 20 µg was used for SDS-PAGE and immunoblot analyses.
Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis
Stained gel lanes were excised in two parts (upper and lower), and proteins were digested with trypsin according to the procedure described previously 15 Using Mascot (Matrix Science, UK) we searched extracted MS/MS spectra against the SwissProt database (Mammalia). We allowed common variable modifications and one missed tryptic cleavage; peptide tolerance was ± 10 ppm and MS/MS tolerance was ± 0.8 Da.
Proteins that (1) were identified by only one specific MS/MS spectrum or (2) presented exogenous contaminations like keratins, trypsin, or immunoglobulins were not considered in further evaluations.
Protein Quantification
We used two previously detailed protein quantification methods16 that are both based on Ensuring the significance of rPVs, required that at least two peptide ratios had assigned PVs totaling 100,000 volume units. Proteins were regarded as specifically (co-) purified when their rPV values were higher than 10. The molar amounts of different proteins were compared by using abundancenorm values (as in Fig. 1 ), calculated as the sum of all assigned peak volumes (totalPV) divided by the number of MS-accessible amino acids (sequence of tryptic peptides with masses between 740 and 3000 Da under the MS settings used). Immunoblots showing specific copurification of MLC1 in an AP with anti-GlialCAM (samples and antibodies labeled as before). "-" indicates no sample was loaded.
Genetic Analysis
The diagnosis of MLC was established by MRI criteria. with ENSG00000165478 as reference sequence.
Immunofluorescent and Electron Microscopic Studies in Tissue
Tissue immunohistochemistry was performed as previously described 5, 7 . For electron 
Supplementary Table 1. Primers for Sequence Analysis of HEPACAM

Primary Culture and Adenoviral Transduction
Rat primary astrocytes were prepared as described previously 13 with some modifications.
Cortex and hippocampus were removed from newborn (1 to 3 days old) Sprague Dawely rats Construction of adenovirus expressing wild-type HA-tagged human MLC1 has been described 13 . In a similar manner, we constructed and produced adenoviruses expressing three copies of the flag epitope fused to wild-type human GlialCAM or to human GlialCAM containing either the recessive mutations p.Arg92Gln, p.Arg98Cys, and p.Ser196Tyr or the dominant mutations p.Arg92Trp and p.Gly89Asp.
To infect astrocytes, we added adenoviruses at multiplicity of infection (MOI) 3 and kept them overnight at 37°C. Cells were washed, and then fresh medium was added. Astrocytes were incubated at 37°C until they were processed.
Results
MLC1-Interacting Proteins
We used a method of quantitative proteomic analysis of affinity-purified MLC1 to identify candidate genes for MLC. Independent affinity-purification experiments with MLC1 were performed with solubilized brain membranes and three different antibodies directed against peptides from the MLC1 N terminus ( Immunoblots with antibodies against GlialCAM ( Supplementary Fig. 3 ) demonstrated that the protein was present in all purifications with all different MLC1 antibodies (Fig. 1C) . Not all GlialCAM coimmunoprecipitated with MLC1 ( Fig. 1C) , possibly because not all GlialCAM is associated with MLC1 or because the coassembly dissolves during membrane protein solubilization. We confirmed the interaction between GlialCAM and MLC1 in reverse affinity purification experiments by using an antibody against GlialCAM that specifically coimmunoprecipitated GlialCAM and MLC1 from brain membranes. In the reverse purification, nearly all MLC1 was associated with GlialCAM ( 
HEPACAM Mutations in MLC Patients without MLC1 Mutations
We analyzed the exons and surrounding intronic regions of HEPACAM in 40 patients from 34
families from around the world. In ten patients from eight families, we found two HEPACAM mutations (Table 1) . Sequence analysis of HEPACAM in the parents showed autosomalrecessive inheritance of the two mutations in all cases except for one family with a de novo mutation. None of the patients had two mutations that abrogate expression of GlialCAM. In 18
patients from 16 families, we found one HEPACAM mutation, which was either inherited from a parent or arose de novo (Table 1 ). In 12 patients from ten families, we did not find HEPACAM mutations.
The observed nucleotide changes in HEPACAM are most likely pathogenic. They were not observed in 400 control chromosomes. All missense mutations affect amino acids that are conserved across a wide range of species (Fig. 2B ). Nine missense mutations affect amino acids in the predicted immunoglobulin domains in the extracellular part of GlialCAM ( Fig.s 2A and 2C). p.Pro148Ser affects a residue between the two immunoglobulin domains. All these amino acid substitutions are predicted to affect protein function (SIFT). The substitution of residue Leu23 by His is predicted to affect the signal peptide, which spans the first 33 amino acids (SignalP 3.0 Server). Patient EL775 had two missense mutations, both inherited from the father. p.Asp128Asn is probably the pathogenic mutation because it is also observed in patients EL158 and EL708. In 12 patients from ten families, neither MLC1 nor HEPACAM mutations were found. In these families, we could not exclude linkage with both the MLC1 and HEPACAM loci with certainty (data not shown). The possibility of hidden MLC1 or HEPACAM mutations cannot, therefore, be excluded, and it is not certain that there must be a third gene mutated in MLC.
Inheritance, Phenotypes, and Mutations
All ten patients with two HEPACAM mutations inherited in an autosomal-recessive fashion had the classical phenotype (Supplementary Table 2 ). They had infantile-onset macrocephaly and delayed-onset motor deterioration, epilepsy, and cognitive decline of variable severity.
The MRI showed typical white matter abnormalities in all stages of the disease ( Supplementary Fig. 1 ). The parents were normal, but two of the 16 had macrocephaly (Table   1 ).
All 18 patients with one HEPACAM mutation had the improving phenotype (Supplementary Table 3 ). They developed macrocephaly within the first year. In two of the 18, the head circumference subsequently normalized. The motor capabilities became normal or almost normal. Some patients had normal intelligence, and others, with intelligence quoficients (IQs) between 50 and 75, had a stable mental retardation. Three of the mentally retarded patients also had autism or pervasive developmental disorder not otherwise specified according to DSM IV criteria. In summary, 11 of the 18 patients became clinically normal, apart from macrocephaly. MRI initially showed typical abnormalities but, on follow up, major improvement or normalization ( Supplementary Fig. 1 ). For 13 patients from 11 families, eight of the 11 parents with the mutated allele had macrocephaly, one had transient macrocephaly as a child, and two never had macrocephaly as far as they could remember. Regarding the five remaining patients, the HEPACAM mutation arose de novo in three, and their parents had normal head circumference; DNA of the parents was not available in two. Only one of the parents without the mutated allele had macrocephaly. The family data suggest autosomal- The effect of mutations located in the extracellular domain of GlialCAM was studied in cultures of primary astrocytes, the cell type with the highest natural abundance of both MLC1 and GlialCAM. After adenoviral-mediated expression, lysates of astrocytes were analyzed by immunoblot and immunofluorescence. Expression levels of all types of mutant GlialCAM were not statistically different from wild-type GlialCAM ( Supplementary Fig. 4 ).
Supplementary
Immunofluorescence revealed that MLC1 and GlialCAM are located in cell-cell junctions between astrocytes (Fig. 4A) . Coexpression of wild-type MLC1 and GlialCAM containing the recessive mutations p.Arg92Gln or p.Arg98Cys resulted in diffuse intracellular MLC1 and
GlialCAM localization with partial enrichment in cell membranes but not specifically in cell junctions ( Fig. 4B and Supplementary Fig. 5A ). No defect was found for the mutation p.Ser196Tyr (Supplementary Fig. 5C ). Similar mislocalization of MLC1 and GlialCAM was observed after coexpression of wild-type MLC1 and GlialCAM containing the dominant mutations p.Arg92Trp and p.Gly89Asp ( Fig.s 4D and Supplementary Fig. 5D ).
To MLC1, wild-type GlialCAM and GlialCAM containing the indicated mutation (B, p.Arg98Cys; E, p.Gly89Asp) at a MOI ratio of 3:2:2. Cells were fixed, permeabilized and then, immunofluorescence was performed using a rabbit polyclonal antibody against human MLC1 (green) and a monoclonal antibody detecting GlialCAM protein (red).
Nuclei were stained using DAPI (blue). Colocalization between the green and the red channel is shown in yellow.
Images correspond to representative cells from four independent experiments. Scale bar: 20 µm. The fact that genetic-linkage studies failed to identify a second gene was ascribed to further genetic heterogeneity 9, 10 . We recently identified two presumably autosomal recessive, phenotypes among MLC patients without MLC1 mutations11, corroborating the notion of genetic heterogeneity. We now show that the genetic heterogeneity does not involve the gene but the mode of inheritance. We circumvented the problem of genetic heterogeneity by using a proteomic approach. This method is validated by the discovery of HEPACAM (hepatic and glial cell adhesion molecule, MIM 611642) as a gene disrupted in MLC and can be considered in the future to identify disease genes for other rare or genetically heterogeneous disorders.
13
We prefer the name GlialCAM above HepaCAM for the related protein. Although the protein was first isolated from liver and called HepaCAM 21 , it was subsequently found to be predominantly expressed in the central nervous system and was renamed GlialCAM 18 . In the present paper, we show that mutations in HEPACAM lead to a neurological phenotype without any sign of liver involvement.
That mutations in one gene cause both autosomal-recessive and -dominant disease is rare but not unique. It has been described for a few other genes, including LMNA (MIM Interestingly, GlialCAM and not MLC1 is detected in myelin, the place where most vacuoles are found in MLC 2 . GlialCAM is not obligatorily associated with MLC1, indicating that it might have other functions by itself or in association with other molecules. Recently, it has been suggested that MLC1 interacts with the β1 subunit of the Na,K-ATPase pump 28 . We did not detect this protein in our affinity purifications. Further studies on MLC1-interacting proteins might provide better insights into the pathophysiology of MLC.
GlialCAM is an interesting protein. In 60% of the families with dominant HEPACAM mutations, the affected persons in fact display benign familial macrocephaly (MIM 153470).
They have macrocephaly, but they are otherwise normal. MRI shows large but normal brains.
The parents did not undergo MRI as children, and a transient leukoencephalopathy was not documented in any of them. Benign familial macrocephaly is most likely genetically heterogeneous, and HEPACAM is likely to be one of the related genes. Another interesting finding is that in 40% of the patients with a dominant HEPACAM mutation, macrocephaly, and mental retardation with or without autism, which are known to be associated features, persist 29 . This clinical syndrome is probably genetically heterogeneous, and specific HEPACAM mutations could cause it. The fact that single HEPACAM mutations might be associated with 
